# Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects

> **NCT05845996** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 56 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** SAR441344
- **DRUG:** placebo
- **BIOLOGICAL:** Keyhole limpet hemocyanin

## Key facts

- **NCT ID:** NCT05845996
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-08
- **Primary completion:** 2020-04-10
- **Final completion:** 2020-04-10
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05845996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05845996, "Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05845996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*